Abstract:The identification of 16S rDNA biomarkers from respiratory samples to describe the continuum of clinical disease states within persons having cystic fibrosis (CF) has remained elusive. We sought to combine 16S, metagenomics, and metabolomics data to describe multiple transitions between clinical disease states in 14 samples collected over a 12-month period in a single person with CF. We hypothesized that each clinical disease state would have a unique combination of bacterial genera and volatile metabolites as a potential signature that could be utilized as a biomarker of clinical disease state. Taxonomy identified by 16S sequencing corroborated clinical culture results, with the majority of the 109 PCR amplicons belonging to the bacteria grown in clinical cultures (Escherichia coli and Staphylococcus aureus). While alpha diversity measures fluctuated across disease states, no significant trends were present. Principle coordinates analysis showed that treatment samples trended toward a different community composition than baseline and exacerbation samples. This was driven by the phylum Bacteroidetes (less abundant in treatment, log2 fold difference −3.29, p = 0.015) and the genus Stenotrophomonas (more abundant in treatment, log2 fold difference 6.26, p = 0.003). Across all sputum samples, 466 distinct volatile metabolites were identified with total intensity varying across clinical disease state. Baseline and exacerbation samples were rather uniform in chemical composition and similar to one another, while treatment samples were highly variable and differed from the other two disease states. When utilizing a combination of the microbiome and metabolome data, we observed associations between samples dominated Staphylococcus and Escherichia and higher relative abundances of alcohols, while samples dominated by Achromobacter correlated with a metabolomics shift toward more oxidized volatiles. However, the microbiome and metabolome data were not tightly correlated; examining both the metagenomics and metabolomics allows for more context to examine changes across clinical disease states. In our study, combining the sputum microbiome and metabolome data revealed stability in the sputum composition through the first exacerbation and treatment episode, and into the second exacerbation. However, the second treatment ushered in a prolonged period of instability, which after three additional exacerbations and treatments culminated in a new lung microbiome and metabolome.

Uncovering cystic fibrosis patient profiles and exposome associations through unsupervised multidimensional phenotyping

TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease

A Strategy for High-Dimensional Multivariable Analysis Classifies Childhood Asthma Phenotypes from Genetic, Immunological, and Environmental Factors

Longitudinal Associations of the Cystic Fibrosis Airway Microbiome and Volatile Metabolites: A Case Study

Robust identification of environmental exposures and community characteristics predictive of rapid lung disease progression

Temporal Exploration of COPD Phenotypes: Insights from the COPDGene and SPIROMICS Cohorts

Identification of Exhaled Metabolites Correlated with Respiratory Function and Clinical Features in Adult Patients with Cystic Fibrosis by Real-Time Proton Mass Spectrometry

Network Analysis to Identify Multi-Omic Correlations in the Lower Airways of Children With Cystic Fibrosis

Case Study: Analyzing CFTR Mutations and SNPs in Pulmonary Fibrosis Patients with Unclear Symptoms

Serum-Based Proteomics Profiling in Adult Patients with Cystic Fibrosis

Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci

Biochemical assessment in a cohort of pediatric patients with cystic fibrosis

Multi-omics subtyping pipeline for chronic obstructive pulmonary disease

Incorporating Comprehensive Assessment Parameters to Better Characterize and Plan Rehabilitation for Persons with Chronic Obstructive Pulmonary Disease

Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity

Precision environmental health monitoring by longitudinal exposome and multi-omics profiling

Subpopulations of children with multiple chronic health outcomes in relation to chemical exposures in the ECHO-PATHWAYS consortium

Clustering high dimensional mixed data to uncover sub-phenotypes:joint analysis of phenotypic and genotypic data

The Longitudinal Microbial and Metabolic Landscape of infant Cystic Fibrosis: The gut-lung axis

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations

Association of factors with childhood asthma and allergic diseases using latent class analysis